Taken together, PGE2 and its receptors, particularly EP1 and EP4, are implicated in driving CRC progression, suggesting that antagonists targeting these receptors may represent a promising therapeutic strategy for CRC treatment. Here, PTGER1 is linked to colorectal carcinoma.